Abstract
The polymorphic gene expression of CYP2C19 causes individual variability in drug metabolism and thereby in pharmacologic and toxicologic responses. We genotyped 286 patients and their donors for the CYP2C19 gene who underwent allogeneic transplantation for various diseases and analyzed their outcome. Patients were classified as: poor metabolizers (PMs; 3.1%), intermediate metabolizers (IMs; 24.5%) and extensive metabolizers (EMs; 72.5%). Patients genotyped as PMs had significant higher hepato- and nephrotoxicities compared to IMs or EMs. Maximum bilirubin and serum creatinine levels measured after transplant were approximately twofold higher than those of EMs or IMs. The increased toxicity resulted in an increased 4-year estimate for transplant-related mortality (TRM) with 50±18.6% for PMs compared to 25.1±3.7% for EMs (P<0.018) and 22.7 ±5.6% for IMs (P<0.042), whereas no significant influence for relapse rate, overall survival or incidence of acute graft-versus-host disease grade 2–4 were found between the groups. Multivariate analysis including all potential factors that might influence TRM confirmed that the genotype of CYP2C19 is an independent factor, which influenced TRM significantly. These results suggest that genotyping for CYP450 2C19 can help to identify patients with higher risk for TRM.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Daly AK . Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol 2003; 17: 27–41.
Desta Z, Zhao X, Shin JG, Flockhart DA . Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin Pharmacol Ther 2005; 77: 40.
Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P4502C19. Pharmacogenomics J 2005; 5: 365–373.
Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G et al. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 2003; 59: 103–109.
Ishida Y, Goto Y, Kondo T, Kurata M, Nishio K, Kawai S et al. Eradication rate of Helicobacter pylori according to genotypes of CYP2C19, IL-1B, and TNF-A. Int J Med Sci 2006; 3: 135–140.
Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kabayashi N, Oyasu K et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003; 17: 259–265.
Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S et al. Impact of clarithromycin resistence and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 2003; 15: 27–33.
Kropp S, Lichtinghagen R, Winterstein K, Schlimme J, Schneider U . Cytochrome p-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry. Clin Lab 2006; 52: 237–240.
Mikus G, Schöwel V, Drzewinska M, Rengelshausen J, Ding R, Riedel KD et al. Potent cytochrome P4502C19 genotype-related interaction between voriconazol and the cytochrome P4503A4 inhibitor ritonavir. Clin Pharmacol Therap 2006; 80: 126–135.
Hulot J-S, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C et al. Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108: 2244–2247.
Ottinger HD, Ferencik S, Beelen DW, Lindemann M, Peceny R, Elmaagacli AH et al. Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched unrelated donors. Blood 2003; 102: 1131.
Elmaagacli AH, Peceny R, Steckel N, Trenschel R, Grosse-Wilde H, Schaefer UW et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 2003; 101: 446.
Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al. Bone marrow transplantation. N Engl J Med 1975; 292: 895.
Maniatis T, Fritsch EF, Sambrook J . Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press: Harbor, NY, USA, 1982.
Kaplan EL, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
Cox DR . Regression models and life-tables. J R Stat Soc 1972; 34: 187.
Luo H-R, Poland RE, Lin K-M, Wan YJY . Genetic polymorphism of cytochrom P4502C19 in Mexican Americans: a cross-ethnic comparative study. Clin Pharmacol Ther 2006; 80: 33–40.
Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P et al. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Pharmacogenetics 2005.
Elmaagacli AH, Koldehoff M, Hindahl H, Steckel NK, Trenschel R, Peceny R et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute GVHD in patients who underwent an allogeneic transplantation. Transplantation 2006; 81: 247–254.
Boucher HW, Groll AH, Chiou CC, Walsh TJ . Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004; 64: 1997–2000.
Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M . Pharmacokinetics of voriconazole and cytochrome P4502C19 genetic status. Clin Pharmacol Ther 2004; 75: 587–588.
Wilkinson GR . Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211–2221.
Andersson T, Flockhart DA, Goldstein DB, Goldstein DB, Huang SM, Kroetz DL et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005; 78: 559–581.
Acknowledgements
We thank Christiane Schary, Melanie Kroll, Silke Gottwald and Ines Riepenhoff (all Essen, Germany) for their excellent technical assistance with PCR analyses. This work was supported by grants from Deutsche Krebshilfe 70-3093-El4 and Kulturstiftung Essen (05 032 Elmaagacli).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Elmaagacli, A., Koldehoff, M., Steckel, N. et al. Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant 40, 659–664 (2007). https://doi.org/10.1038/sj.bmt.1705786
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705786
Keywords
This article is cited by
-
Chemotherapy-induced niche perturbs hematopoietic reconstitution in B-cell acute lymphoblastic leukemia
Journal of Experimental & Clinical Cancer Research (2018)
-
Identification and Utilization of Donor and Recipient Genetic Variants to Predict Survival After HCT: Are We Ready for Primetime?
Current Hematologic Malignancy Reports (2015)
-
It takes nerves to recover from chemotherapy
Nature Medicine (2013)
-
Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients
Bone Marrow Transplantation (2011)
-
Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9
Bone Marrow Transplantation (2009)